Treatment of CD19‐positive mixed phenotype acute leukemia with blinatumomab

Chaer, Firas El; Ali, Omer; Sausville, Edward A.; Law, Jennie Y.; Lee, Seung Tae; Duong, Vu H.; Koka, Rima; Singh, Zeba N.; Wong, Jerry; Yared, Jean A.; Griffiths, Elizabeth A.; Emadi, Ashkan

doi:10.1002/ajh.25317

Cited by 20 publications

(16 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, El Chaer et al reported two patients with CD19 + B/myeloid MPAL treated with blinatumomab [26]. Patient 1 who had t(9;22) received blinatumomab due to MRD positivity by flow cytometry at the end of induction therapy with cytarabine, daunorubicin and daily dasatinib.…”

Section: Discussionmentioning

confidence: 99%

Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Mixed-Phenotype Acute Leukemia: A Case Report With Literature Review

Durer

Shafqat

et al. 2019

Immunotherapy

View full text Add to dashboard Cite

Blinatumomab and donor lymphocyte infusion (DLI) combination is a promising cancer therapy, whereby blinatumomab might achieve an initial reduction in leukemic-cell burden using T cells, and after tumor clearance, DLI can potentially stimulate the donor immune system to achieve longer lasting remission. Here, we present a 51-year-old female with mixed phenotype acute leukemia who had a hematologic relapse 3 months after she received total body irradiation-based myeloablative allogeneic hematopoietic stem cell transplantation from an unrelated human leukocyte antigen matched (10/10) donor and achieved complete remission with minimal residual disease negativity by multi-parameter flow cytometry using the combination of blinatumomab and DLI. To the best of our knowledge, this is the first report to describe the use of blinatumomab and DLI combination therapy in the treatment of B/myeloid mixed phenotype acute leukemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Mixed-Phenotype Acute Leukemia: A Case Report With Literature Review

Durer

Shafqat

et al. 2019

Immunotherapy

View full text Add to dashboard Cite

show abstract

“…Operatively, it is suggested to perform a full analysis of the above-mentioned markers, both at diagnosis and at follow-up, possibly adopting the same set of tubes and combinations of antibody/fluorochrome [ 4 ]. Of note, such a comprehensive MFC-MRD monitoring may allow to disclose some specific phenotype shifts that could offer the chance to exploit novel target treatments developed for other malignancies (as reported for the clinical case of a CD19-positive AML relapse, successfully treated with DLI infusions in combination with anti-CD19 blinatumomab [ 5 ], also in keeping with the use of such bispecific T-cell engager (BiTE) in patients with mixed phenotype acute leukemias [ 6 ]).…”

Section: Acute Myeloid Leukemia (Aml)mentioning

confidence: 99%

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges

Riva¹,

Nasillo²,

Ottomano³

et al. 2021

Cancers

View full text Add to dashboard Cite

Along with the evolution of immunophenotypic and molecular diagnostics, the assessment of Minimal Residual Disease (MRD) has progressively become a keystone in the clinical management of hematologic malignancies, enabling valuable post-therapy risk stratifications and guiding risk-adapted therapeutic approaches. However, specific prognostic values of MRD in different hematological settings, as well as its appropriate clinical uses (basically, when to measure it and how to deal with different MRD levels), still need further investigations, aiming to improve standardization and harmonization of MRD monitoring protocols and MRD-driven therapeutic strategies. Currently, MRD measurement in hematological neoplasms with bone marrow involvement is based on advanced highly sensitive methods, able to detect either specific genetic abnormalities (by PCR-based techniques and next-generation sequencing) or tumor-associated immunophenotypic profiles (by multiparametric flow cytometry, MFC). In this review, we focus on the growing clinical role for MFC-MRD diagnostics in hematological malignancies—from acute myeloid and lymphoblastic leukemias (AML, B-ALL and T-ALL), to chronic lymphocytic leukemia (CLL) and multiple myeloma (MM)—providing a comparative overview on technical aspects, clinical implications, advantages and pitfalls of MFC-MRD monitoring in different clinical settings.

show abstract

“…There is growing evidence that these therapies can also be utilized in the treatment of MPAL. Recent case reports and small retrospective reviews support the use of CD19 BITE cells and CART cells as efficacious treatments for refractory MPAL [ 77 , 78 , 79 , 80 ]. A recent case series from Bartram et al out of the United Kingdom presented three pediatric cases of refractory MPAL that successfully utilized Blinatumomab as a bridge to transplant, including in a patient with a significant CD19-negative blast component [ 81 ].…”

Section: Novel Approachesmentioning

confidence: 99%

Pediatric Mixed-Phenotype Acute Leukemia: What’s New?

Batra

Ross

2021

Cancers

View full text Add to dashboard Cite

Mixed-phenotype acute leukemias (MPAL) are rare in children and often lack consensus on optimal management. This review examines the current controversies and emerging paradigms in the management of pediatric MPAL. We examine risk stratification, outcomes of recent retrospective and prospective collaborative trials, and the role of transplantation and precision genomics, and outline emerging targets and concepts in this rare entity.

show abstract

Treatment of CD19‐positive mixed phenotype acute leukemia with blinatumomab

Cited by 20 publications

References 6 publications

Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Mixed-Phenotype Acute Leukemia: A Case Report With Literature Review

Concomitant Use of Blinatumomab and Donor Lymphocyte Infusion for Mixed-Phenotype Acute Leukemia: A Case Report With Literature Review

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges

Pediatric Mixed-Phenotype Acute Leukemia: What’s New?

Contact Info

Product

Resources

About